MCID: AMP013
MIFTS: 48

Ampulla of Vater Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Ampulla of Vater Cancer

MalaCards integrated aliases for Ampulla of Vater Cancer:

Name: Ampulla of Vater Cancer 12 12 15
Ampulla of Vater Carcinoma 12 15
Ampulla of Vater Neoplasm 12 15
Ampullary Carcinoma 12 59
Malignant Tumour of Ampulla of Vater 12
Carcinoma of the Ampulla of Vater 59
Tumor of the Ampulla of Vater 12
Carcinoma of Ampulla of Vater 12
Ampulloma 59

Characteristics:

Orphanet epidemiological data:

59
carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:10020 DOID:10022 DOID:4932
ICD10 33 C24.1
ICD9CM 35 156.2
SNOMED-CT 68 93668007
Orphanet 59 ORPHA300557
ICD10 via Orphanet 34 C24.1
UMLS via Orphanet 74 C0262401

Summaries for Ampulla of Vater Cancer

Disease Ontology : 12 An ampulla of Vater cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Ampulla of Vater Cancer, also known as ampulla of vater carcinoma, is related to ampulla of vater adenocarcinoma and adenosquamous carcinoma. An important gene associated with Ampulla of Vater Cancer is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Development EGFR signaling pathway and Cytoskeletal Signaling. The drugs Oxaliplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and ovary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Ampulla of Vater Cancer

Diseases related to Ampulla of Vater Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 275)
# Related Disease Score Top Affiliating Genes
1 ampulla of vater adenocarcinoma 31.4 CDX2 KRT17 KRT20 KRT7 MUC1 MUC2
2 adenosquamous carcinoma 30.2 KRAS KRT7 MUC1 TP53
3 lynch syndrome 29.9 KRAS MUC2 TP53
4 cholecystitis 29.9 MUC1 MUC2 MUC6 TP53
5 ovarian cancer 29.8 KRAS KRT7 MUC1 MUC2 TP53
6 adenocarcinoma 29.7 HRAS KRAS MUC1 TP53
7 gallbladder cancer 29.6 KRAS MUC1 MUC2 TP53
8 bladder cancer 29.4 HRAS KRAS KRT20 MUC2 TP53
9 cholangiocarcinoma 29.2 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
10 gastric cancer 29.1 CDX2 KRAS KRT20 MUC2 MUC6 TP53
11 intrahepatic cholangiocarcinoma 29.0 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
12 ampulla of vater squamous cell carcinoma 11.4
13 ampulla of vater adenosquamous carcinoma 11.4
14 large cell neuroendocrine carcinoma 10.5
15 gastrointestinal stromal tumor 10.5
16 adenocarcinoma of the gallbladder and extrahepatic biliary tract 10.4
17 squamous cell carcinoma of gallbladder and extrahepatic biliary tract 10.4
18 carcinoid syndrome 10.3
19 schimmelpenning-feuerstein-mims syndrome 10.3 HRAS KRAS
20 bile duct cysts 10.3 HRAS KRAS
21 periampullary adenoma 10.3 HRAS KRAS
22 secondary hypertrophic osteoarthropathy 10.3 HRAS KRAS
23 paronychia 10.3 HRAS KRAS
24 ovarian cystadenocarcinoma 10.3 HRAS KRAS
25 acneiform dermatitis 10.3 HRAS KRAS
26 lung adenoid cystic carcinoma 10.3 HRAS KRAS
27 core binding factor acute myeloid leukemia 10.3 HRAS KRAS
28 alveoli adenoma 10.3 KRAS KRT7
29 polyposis, skin pigmentation, alopecia, and fingernail changes 10.3 CDX2 MUC2
30 microinvasive gastric cancer 10.3 CDX2 MUC2
31 syringocystadenoma papilliferum 10.2 KRAS MUC1
32 chronic cholangitis 10.2 CDX2 MUC2
33 nasal cavity cancer 10.2 CDX2 KRT7
34 conn's syndrome 10.2
35 squamous cell carcinoma 10.2
36 epithelial predominant wilms' tumor 10.2 CDX2 KRT7
37 endosalpingiosis 10.2 KRT7 MUC1
38 nodular hidradenoma 10.2 KRT7 MUC1
39 parachordoma 10.2 KRT7 MUC1
40 sertoli-leydig cell tumor 10.2 KRT7 MUC1
41 hidradenoma 10.2 KRT7 MUC1
42 spindle cell sarcoma 10.2 KRT7 MUC1
43 secretory meningioma 10.2 KRT7 MUC1
44 sclerosing hemangioma 10.2 KRT7 MUC1
45 middle ear adenoma 10.2 KRT7 MUC1
46 lipoadenoma 10.2 KRT7 MUC1
47 monophasic synovial sarcoma 10.2 KRT7 MUC1
48 well-differentiated liposarcoma 10.2 KRT7 MUC1
49 hepatoid adenocarcinoma 10.2 CDX2 MUC1
50 sigmoid neoplasm 10.2 HRAS KRAS

Graphical network of the top 20 diseases related to Ampulla of Vater Cancer:



Diseases related to Ampulla of Vater Cancer

Symptoms & Phenotypes for Ampulla of Vater Cancer

GenomeRNAi Phenotypes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.8 HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.8 KRAS
3 Decreased viability GR00221-A-1 9.8 HRAS KRAS
4 Decreased viability GR00221-A-2 9.8 HRAS KRAS
5 Decreased viability GR00221-A-3 9.8 HRAS
6 Decreased viability GR00301-A 9.8 KRAS
7 Decreased viability GR00381-A-1 9.8 KRAS
8 Decreased viability GR00402-S-2 9.8 HRAS KRAS MUC1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 KRT17
10 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.72 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 KRAS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.72 KRT17
13 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.72 KRT17
15 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.72 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.72 HRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.72 KRT17
18 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.72 HRAS KRAS KRT17
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.72 KRT17
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.72 KRT17
21 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.72 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 KRT17
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.72 HRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.72 KRT17
25 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.72 KRT17
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 KRAS KRT17
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.72 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 KRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.72 HRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.72 KRAS

MGI Mouse Phenotypes related to Ampulla of Vater Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.43 CDX2 HRAS KRAS KRT17 MUC2 TP53
2 neoplasm MP:0002006 9.02 CDX2 HRAS KRAS MUC2 TP53

Drugs & Therapeutics for Ampulla of Vater Cancer

Drugs for Ampulla of Vater Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
5
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
6
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
8 Antidotes Phase 3,Phase 1,Phase 2
9 Vitamin B Complex Phase 3,Phase 1,Phase 2
10 Trace Elements Phase 3,Phase 1,Phase 2
11 Vitamins Phase 3,Phase 1,Phase 2
12 Vitamin B9 Phase 3,Phase 1,Phase 2
13 Folate Phase 3,Phase 1,Phase 2
14 Micronutrients Phase 3,Phase 1,Phase 2
15 Protective Agents Phase 3,Phase 1,Phase 2
16 Antibiotics, Antitubercular Phase 3,Not Applicable
17 Anti-Bacterial Agents Phase 3,Not Applicable
18 Hematinics Phase 3
19 Emetics Phase 3
20 Antiemetics Phase 3
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Bevacizumab Approved, Investigational Phase 2 216974-75-3
24
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
25
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
26
Coal tar Approved Phase 1, Phase 2 8007-45-2
27
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
28
s 1 (combination) Phase 2
29 Antimetabolites Phase 2,Phase 1
30 Immunologic Factors Phase 2,Phase 1
31 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
32 Immunosuppressive Agents Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 2,Phase 1
34 Antiviral Agents Phase 2,Phase 1
35 Antimitotic Agents Phase 2,Phase 1
36 Immunoglobulin G Phase 2
37 Antibodies Phase 2,Phase 1
38 Mitogens Phase 2
39 Antibodies, Monoclonal Phase 2
40 Immunoglobulins Phase 2,Phase 1
41 Endothelial Growth Factors Phase 2
42 Angiogenesis Modulating Agents Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Calcium, Dietary Phase 1, Phase 2
45 Topoisomerase Inhibitors Phase 1, Phase 2
46 topoisomerase I inhibitors Phase 1, Phase 2
47 Antineoplastic Agents, Phytogenic Phase 1, Phase 2,Phase 2
48 Albumin-Bound Paclitaxel Phase 1, Phase 2,Phase 2
49 Immunotoxins Phase 1, Phase 2
50
Pancrelipase Approved, Investigational Phase 1,Early Phase 1,Not Applicable 53608-75-6

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
2 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
3 Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
4 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed NCT00660699 Phase 2 Gemcitabine;Docetaxel
5 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
6 Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
7 Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT02333188 Phase 1, Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
8 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
9 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
10 Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
11 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
12 A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Recruiting NCT02908451 Phase 1
13 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
14 ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT02351765 Phase 1 Acelarin;Cisplatin
15 Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer Unknown status NCT02238613 Not Applicable
16 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Unknown status NCT02656134
17 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131 Not Applicable
18 Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage Completed NCT01789502 Not Applicable
19 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276 Not Applicable
20 Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation Completed NCT02477228 Not Applicable
21 Fatigue and Pancreas and Bile Duct Cancer Study Completed NCT00902759 Early Phase 1
22 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607 Not Applicable
23 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864 Not Applicable
24 Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy Completed NCT00639314 Not Applicable
25 Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy Completed NCT00628186 Not Applicable
26 Endobiliary RFA for Unresectable Malignant Biliary Strictures Recruiting NCT01844245 Not Applicable
27 Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors Recruiting NCT02665494
28 EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice Recruiting NCT03494023
29 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615 Not Applicable
30 Periampullary Lesions Via ERCP in Assuit University Hospital Recruiting NCT03185390 Not Applicable
31 T-EUS for Gastrointestinal Disorders: A Multicenter Registry Recruiting NCT01522573
32 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059 Not Applicable
33 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Recruiting NCT01438385
34 Effect of Cap-assisted Esophagogastroduodenoscopy on Observation of Major Duodenal Papilla Recruiting NCT03219619 Not Applicable
35 Margin Status After Pancreaticoduodenectomy for Cancer Active, not recruiting NCT03267966 Not Applicable

Search NIH Clinical Center for Ampulla of Vater Cancer

Genetic Tests for Ampulla of Vater Cancer

Anatomical Context for Ampulla of Vater Cancer

MalaCards organs/tissues related to Ampulla of Vater Cancer:

41
Lung, Breast, Ovary, Prostate, Pancreas, Thymus, Appendix

Publications for Ampulla of Vater Cancer

Articles related to Ampulla of Vater Cancer:

(show all 34)
# Title Authors Year
1
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. ( 27611608 )
2018
2
Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. ( 29452703 )
2018
3
Impact of preoperative endoscopic cholangiography and biliary drainage in Ampulla of Vater cancer. ( 29549909 )
2018
4
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. ( 30451797 )
2018
5
Ampulla of Vater carcinoma: Molecular landscape and clinical implications. ( 30487949 )
2018
6
Proposed new staging system for ampulla of Vater cancer with greater discriminatory ability: multinational study from eastern and western centers. ( 28660632 )
2017
7
PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. ( 28502094 )
2017
8
Transduodenal Ampullectomy for the Treatment of Early-Stage Ampulla of Vater Cancer. ( 26546182 )
2016
9
Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. ( 26974670 )
2016
10
Ampulla of Vater carcinoma in real-world clinical practice: a case series. ( 25908045 )
2015
11
Metachronous Ampulla of Vater Carcinoma after Curative-Intent Surgery for Klatskin Tumor. ( 26305204 )
2015
12
Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. ( 25775067 )
2015
13
Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. ( 26603157 )
2015
14
Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. ( 25367337 )
2014
15
Clinical value of serum CA19-9 as a prognostic factor for the ampulla of Vater carcinoma. ( 23933785 )
2013
16
Proposed indications for limited resection of early ampulla of Vater carcinoma: clinico-histopathological criteria to confirm cure. ( 22203456 )
2012
17
Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. ( 21882202 )
2012
18
Surgical outcomes and prognostic factors for ampulla of Vater cancer. ( 21737384 )
2011
19
Significance analysis of histologic type and perineural invasion as prognostic factors after curative resection of ampulla of Vater carcinoma. ( 20698243 )
2010
20
[Determinants of long-term survival after pancreaticoduodenectomy for ampulla of Vater carcinoma]. ( 20223115 )
2009
21
Spontaneous choledochoduodenal fistula after metallic biliary stent placement in a patient with ampulla of vater carcinoma. ( 20431778 )
2009
22
Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. ( 19032444 )
2009
23
Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. ( 19394162 )
2009
24
Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. ( 18712568 )
2008
25
Periampullary choledochoduodenal fistula associated with ampulla of Vater carcinoma. ( 17404887 )
2007
26
Factors influencing recurrence after curative resection for ampulla of Vater carcinoma. ( 17326125 )
2007
27
The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. ( 18019683 )
2007
28
Transduodenal local resection for low-risk group ampulla of vater carcinoma. ( 18158802 )
2007
29
Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer. ( 16506371 )
2006
30
Can endoscopic resection be applied for early stage ampulla of Vater cancer? ( 16650538 )
2006
31
Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11. ( 15024645 )
2004
32
Expression of cyclooxygenase-2 and its correlation with clinicopathologic factors of ampulla of vater cancer. ( 12692419 )
2003
33
Clinics in diagnostic imaging (79). Ampulla of Vater carcinoma. ( 12680532 )
2002
34
Prognostic value of MIB-1 index and DNA ploidy in resectable ampulla of Vater carcinoma. ( 10203085 )
1999

Variations for Ampulla of Vater Cancer

Expression for Ampulla of Vater Cancer

Search GEO for disease gene expression data for Ampulla of Vater Cancer.

Pathways for Ampulla of Vater Cancer

Pathways related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.22 HRAS KRAS MUC1 TP53
2 12.16 KRT17 KRT20 KRT7 MUC1
3 12.14 HRAS KRAS TP53
4 12.13 HRAS KRAS TP53
5
Show member pathways
12.07 MUC1 MUC2 MUC6
6
Show member pathways
12.02 CDX2 HRAS KRAS MUC2 TP53
7 11.99 HRAS KRAS TP53
8
Show member pathways
11.98 HRAS KRAS TP53
9 11.96 HRAS KRAS TP53
10
Show member pathways
11.94 HRAS KRAS TP53
11
Show member pathways
11.93 HRAS KRAS TP53
12
Show member pathways
11.91 MUC1 MUC2 MUC6
13 11.84 HRAS KRAS TP53
14
Show member pathways
11.83 HRAS KRAS TP53
15 11.78 HRAS KRAS TP53
16 11.76 HRAS KRAS TP53
17 11.75 HRAS KRAS TP53
18 11.7 HRAS KRAS TP53
19
Show member pathways
11.67 MUC1 MUC2 MUC6
20
Show member pathways
11.43 HRAS KRAS MUC1 MUC2 MUC6
21 11.42 HRAS KRAS TP53
22 11.36 HRAS KRAS TP53
23 11.25 HRAS KRAS TP53
24 11.14 HRAS KRAS TP53
25 11.13 HRAS KRAS
26 11.12 HRAS KRAS
27
Show member pathways
11.1 HRAS KRAS
28
Show member pathways
11.04 HRAS KRAS
29 11 HRAS KRAS TP53
30 10.98 HRAS KRAS
31 10.95 HRAS KRAS
32 10.89 HRAS KRAS
33 10.61 HRAS KRAS

GO Terms for Ampulla of Vater Cancer

Cellular components related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.13 KRT17 KRT20 KRT7
2 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.69 KRT17 KRT20 KRT7
2 intrinsic apoptotic signaling pathway GO:0097193 9.52 HRAS TP53
3 cornification GO:0070268 9.5 KRT17 KRT20 KRT7
4 cell aging GO:0007569 9.49 HRAS TP53
5 cellular response to gamma radiation GO:0071480 9.48 HRAS TP53
6 regulation of long-term neuronal synaptic plasticity GO:0048169 9.46 HRAS KRAS
7 intermediate filament organization GO:0045109 9.43 KRT17 KRT20
8 maintenance of gastrointestinal epithelium GO:0030277 9.4 MUC2 MUC6
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
10 Ras protein signal transduction GO:0007265 9.33 HRAS KRAS TP53
11 response to isolation stress GO:0035900 9.26 HRAS KRAS
12 O-glycan processing GO:0016266 9.13 MUC1 MUC2 MUC6
13 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC6

Sources for Ampulla of Vater Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....